US Capitol Capsule: 2014: a year for orphan drugs, anti-PD-1s, 2nd chancers
This article was originally published in Scrip
Executive Summary
The FDA's Center for Drug Evaluation and Research (CDER) in 2014 had its best year in drug approvals since 1996 – clearing 41 new molecular entities (NMEs) and novel biologics over the past 12 months.